六味地黄丸治疗围绝经期综合征的网络药理学研究

Internet Pharmacology Study of Liuwei Dihuang Pills in the Treatment of Perimenopausal Syndrome

目的利用网络药理学研究分析六味地黄丸治疗围绝经期综合征的作用机制。方法通过TCMSP数据库获取其主要成分熟地黄、山药、山茱萸、泽泻、牡丹皮、茯苓的主要化学成分及靶点,根据ADME筛选其中活性成分,通过Gencards、OMIM、DRUGBANK数据库获取围绝经期综合征的主要靶点,利用String平台进行蛋白质互相作用分析,构建PPI网络。利用Metascape平台进行GO和KEGG富集分析,应用CytoScape 3.7.1软件构建“六味地黄丸成分-围绝经期综合征靶点-通路”网络。结果六味地黄丸治疗围绝经期综合征的有效活性成分为山奈酚、β-谷甾醇、豆甾醇及四氢石氨酸等,核心靶点有NCOA2、PTGS2、PRKACA、PGR等。六味地黄丸治疗围绝经期综合征的生物通路主要有雌激素信号通路、内分泌抵抗、胆碱能突触、血清素突触等。结论六味地黄丸可能通过山奈酚、β-谷甾醇、豆甾醇及四氢石氨酸等成分作用于NCOA2、PTGS2、PRKACA、PGR等靶点干预雌激素信号通路、内分泌抵抗、胆碱能突触、血清素突触扥通路治疗围绝经期综合征。

Objective To analyze the mechanism of Liuwei Dihuang pills in the treatment of perimenopausal syndrome by network pharmacology research.Methods The main chemical components and targets of Radix Rehmanniae,Chinese yam,Cornus officinalis,Alisma orientalis,Cortex Moutan and Poria cocos were obtained from the TCMSP database.The active components were screened according to ADME,and the main targets of perimenopausal syndrome were obtained through Gencards,OMIM and DRUGBANK databases.The protein interaction analysis was performed on the String platform to construct PPI network.Metascape platform was used for GO and KEGG enrichment analysis,and CytoScape 3.7.1 software was used to construct the network of"Liuwei Dihuang Pill components-perimenopausal syndrome targets-pathways".Results The effective active ingredients of Liuwei Dihuang pills in the treatment of perimenopausal syndrome were kaempferol,β-sitosterol,stigmasterol and tetrahydrosarcin,etc.The core targets were NCOA2,PTGS2,PRKACA,PGR,etc.The biological pathways of Liuwei Dihuang pills in the treatment of perimenopausal syndrome mainly included estrogen signaling pathway,endocrine resistance,cholinergic synapse,serotonin synapse,etc.Conclusion Liuwei Dihuang pills may act on NCOA2,PTGS2,PRKACA,PGR and other targets through kaempferol,β-sitosterol,stigmasterol and tetrahydrosarcin,etc.to interfere with estrogen signaling pathways,endocrine resistance,cholinergic synapses,serotonin synaptic pathway to treat perimenopausal syndrome.